WO2015182865A1 - Composition pharmaceutique présentant des effets de prévention de la diminution des leucocytes et de restauration des leucocytes, contenant un extrait d'angelica gigas nakai en tant que substance active - Google Patents

Composition pharmaceutique présentant des effets de prévention de la diminution des leucocytes et de restauration des leucocytes, contenant un extrait d'angelica gigas nakai en tant que substance active Download PDF

Info

Publication number
WO2015182865A1
WO2015182865A1 PCT/KR2015/003160 KR2015003160W WO2015182865A1 WO 2015182865 A1 WO2015182865 A1 WO 2015182865A1 KR 2015003160 W KR2015003160 W KR 2015003160W WO 2015182865 A1 WO2015182865 A1 WO 2015182865A1
Authority
WO
WIPO (PCT)
Prior art keywords
white blood
blood cells
angelica
angelica gigas
extract
Prior art date
Application number
PCT/KR2015/003160
Other languages
English (en)
Korean (ko)
Inventor
강재선
지용훈
옥선
표재성
황성우
시레스타 아마타사밀라
김보슬
김동희
이상호
Original Assignee
대우제약 주식회사
경성대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 대우제약 주식회사, 경성대학교 산학협력단 filed Critical 대우제약 주식회사
Publication of WO2015182865A1 publication Critical patent/WO2015182865A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica

Definitions

  • the present invention relates to extracts of Angelica gigas, and more particularly, to extracts of Angelica gigas, which are mainly composed of decusin and decosinol angelate, which are effective in preventing the reduction of leukocytes and restoring leukocytes.
  • Chemotherapy which is a method of removing cancer cells generated in the body, is a systemic treatment method that works on cancer cells spread throughout the body by treating cancer using drugs, that is, anticancer drugs. Since anticancer drugs are designed to remove rapidly growing cancer cells, normal cells are also affected. As a result, after chemotherapy, there are side effects such as anemia, white blood cell and platelet count, mouth loosening, nausea, vomiting, diarrhea, hair loss, and reproductive dysfunction. In the case of chemotherapy, the patient is allowed to rest for an average of two to three weeks to wait for normal cells to recover. Then, the next treatment is performed.
  • the present invention has been invented to solve the above-mentioned conventional problems, and provides a pharmaceutical composition comprising deucin and decosinol angelate as an active ingredient extracted from true donkey as a leukocyte reduction preventing and restoring substance which is effective and has no side effects. It aims to do it.
  • the dosage of the decosin and the decosinol angelate is characterized in that 0.5 mg / kg to 10 mg / kg, preferably the dosage is 0.5 mg / kg to 2 mg / kg .
  • the present invention has the following effects by the above configuration.
  • the present Angelica extract as an active ingredient of decosin and decosinol angelate provided by the present invention has an excellent effect on preventing the reduction of leukocyte levels and restoring the reduced leukocyte levels after chemotherapy as shown in clinical and animal experiments.
  • the pharmaceutical composition of the present invention is prepared according to a method that can be easily carried out by a person skilled in the art, and sucrose, lactose mannose, dextrose, fructose, starch commonly used in the preparation. , Algin, gelatin, cellulose, etc., and polyhydric alcohols such as sorbitol, mannitol, xylitol, lactitol, ribitol, and the like to prevent agglomeration when preparing liquids, and surfactants such as polysorbitan and triton X-100. It includes, and may include acacia rubber, pectin, xanthan gum, agar and the like as a thickener. In addition, stabilizers, preservatives, flavors, sweeteners, lubricants and the like can be further added,
  • the following examples are to confirm the effect on the prevention and recovery of the reduction of white blood cell count using the Angelica Angelica extract containing more than 70% by weight of deckerin and decusin angelate.
  • Benzene was administered intravenously and 0.2 ml / kg was administered for 3 weeks at 2 days intervals.
  • Angelica Angelica extract was administered orally at a dose of 2 mg / kg before and after benzene administration.
  • the control group is a group of natural diet after oral administration of benzene
  • the control group (6,500 cells / ul) had a decrease of about 32% compared to the normal group (9,500 cells / ul).

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un extrait d'Angelica gigas Nakai et, plus spécifiquement un extrait d'Angelica gigas Nakai ayant des effets de prévention d'une diminution du nombre de leucocytes et de restauration du nombre de leucocytes, contenant de la décursine et de l'angélate de décursinol en tant que substances actives. De préférence, l'extrait d'Angelica gigas Nakai de la présente invention contient 70 % en poids ou plus de décursine et d'angélate de décursinol.
PCT/KR2015/003160 2014-05-27 2015-03-31 Composition pharmaceutique présentant des effets de prévention de la diminution des leucocytes et de restauration des leucocytes, contenant un extrait d'angelica gigas nakai en tant que substance active WO2015182865A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0063943 2014-05-27
KR20140063943A KR20150040198A (ko) 2013-10-04 2014-05-27 참당귀 추출물을 유효성분으로 하는 백혈구 감소방지 및 백혈구 회복에 효과를 보이는 약학조성물

Publications (1)

Publication Number Publication Date
WO2015182865A1 true WO2015182865A1 (fr) 2015-12-03

Family

ID=54700095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/003160 WO2015182865A1 (fr) 2014-05-27 2015-03-31 Composition pharmaceutique présentant des effets de prévention de la diminution des leucocytes et de restauration des leucocytes, contenant un extrait d'angelica gigas nakai en tant que substance active

Country Status (2)

Country Link
KR (1) KR20150040198A (fr)
WO (1) WO2015182865A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102035106B1 (ko) * 2019-02-22 2019-10-23 심마니산삼영농조합법인 데커시놀을 유효성분으로 포함하는 혈소판 감소증 또는 림프구 감소증 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010080265A (ko) * 1998-10-22 2001-08-22 정세영 데커신을 포함하는 의약 조성물
KR20050062256A (ko) * 2003-12-20 2005-06-23 박영준 당귀를 함유한 항암제 투여에 의한 빈혈치료를 위한 조혈제
KR20060066175A (ko) * 2004-11-17 2006-06-16 한상필 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 항암 치료보조제 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010080265A (ko) * 1998-10-22 2001-08-22 정세영 데커신을 포함하는 의약 조성물
KR20050062256A (ko) * 2003-12-20 2005-06-23 박영준 당귀를 함유한 항암제 투여에 의한 빈혈치료를 위한 조혈제
KR20060066175A (ko) * 2004-11-17 2006-06-16 한상필 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 항암 치료보조제 조성물

Also Published As

Publication number Publication date
KR20150040198A (ko) 2015-04-14

Similar Documents

Publication Publication Date Title
Mahady et al. In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis
US20130131159A1 (en) Plectranthus amboinicus fraction having anti-arthritis activity
WO2019083321A2 (fr) Composition pour l'antioxydation, l'anti-inflammation ou l'inhibition de la différenciation des ostéoclastes
CN102697845A (zh) 复方多糖中药微生态调节剂
WO2018128408A1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies allergiques telles que l'asthme ou l'atopie, comprenant de la baïcaléine en tant que substance active
WO2014208888A1 (fr) Composition de prévention et de traitement de maladies gastro-intestinales, contenant des huiles essentielles extraites du fruit de litsea japonica
Rukunga et al. The antiplasmodial activity of spermine alkaloids isolated from Albizia gummifera
CN108815218B (zh) 药物组合物及其用途
WO2020096127A1 (fr) Composition comprenant une éponge hydrolysée destinée à soulager l'arthralgie ou la myalgie
WO2018062752A1 (fr) Activateur d'absorption de catéchines destiné à améliorer l'absorption des catéchines dans de petites cellules épithéliales intestinales
WO2015182865A1 (fr) Composition pharmaceutique présentant des effets de prévention de la diminution des leucocytes et de restauration des leucocytes, contenant un extrait d'angelica gigas nakai en tant que substance active
WO2018135912A2 (fr) Composition comprenant du ginsénoside capturé par la curcumine et une nanoparticule lipidique à base de phospholipides en tant que principe actif pour la prévention ou le traitement d'une infection par helicobacter pylori
WO2018190501A1 (fr) Composition anti-inflammatoire contenant un extrait de pédoncule de fleur de ginseng
WO2020116862A1 (fr) Composition pharmaceutique contenant un extrait d'eau florale de lonicera japonica, utilisée dans la prévention ou le traitement d'une nfection à helicobacter pylori
WO2017086653A1 (fr) Composition orale et son procédé de préparation
WO2023042959A1 (fr) Composition anti-inflammatoire comprenant une composition de ginsénoside complexe
WO2022260335A1 (fr) Composition pour améliorer la population microbienne intestinale comprenant du galactose
US9943560B2 (en) Medical compositions containing liquorice extracts with synergistic effect
KR20160111354A (ko) 참당귀 추출물을 유효성분으로 하여 항암제 투여에 의하여 유발되는 백혈구 감소증 치료에 유용한 약학 조성물
WO2013109051A1 (fr) Composition destinée à améliorer la mémoire ou la concentration contenant une fraction d'extrait ayant une teneur accrue en ginsénoside rg3 dérivé du ginseng en tant que principe actif
WO2017020861A1 (fr) Application d'une composition de polygonum capitatum pour résister à helicobacter pylori
KR20080062432A (ko) 포공영 추출물을 함유하는 뉴로키닌 매개 질환 치료 및예방용 약제와 건강식품
KR100733982B1 (ko) 암 치료 및 예방, 항균 및 항산화 효과를 갖는 목초액 유기물
CN112022892B (zh) 蓟属植物的有机提取物的应用
WO2017020279A1 (fr) Utilisations d'une composition comprenant des racines de polygonum capitatum et de coptide dans la préparation de médicaments permettant de résister contre helicobacter pylori

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15800661

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15800661

Country of ref document: EP

Kind code of ref document: A1